Article Details
Retrieved on: 2024-05-25 16:02:46
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article highlights Novartis' use of Information Technology in conducting and presenting clinical trials for Fabhalta, a drug targeting C3 glomerulopathy and other kidney diseases. Tags like renal biopsy, IgA nephropathy, and Novartis AG illustrate the medical context and stakeholders involved.
Article found on: www.prnewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here